[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-350992-105":59,"doc-detail-350992-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","next-generation-anti-dll3-radiopharmaceuticals-targeting-high-grade-neuroendocrine-lung-and-prostate-cancers","Next-generation anti-DLL3 radiopharmaceuticals targeting high-grade neuroendocrine lung and prostate cancers","","Delta-like ligand 3 (DLL3) is a tumor-selective surface protein upregulated in high-grade neuroendocrine cancers, including small-cell lung cancer and neuroendocrine prostate cancer. The study develops anti-DLL3 radioimmunoconjugates using zirconium-89 for diagnostic imaging or lutetium-177 for targeted radioligand therapy. A human antibody panel was screened for high-affinity internalizing clones, reformatted to reduce effector function, and evaluated by pilot immunoPET in SCLC xenograft models.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/next-generation-anti-dll3-radiopharmaceuticals-targeting-high-grade-neuroendocrine-lung-and-prostate-cancers/350992/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/next-generation-anti-dll3-radiopharmaceuticals-targeting-high-grade-neuroendocrine-lung-and-prostate-cancers/350992.png","ImageObject",300,407,{"name":92,"@type":93},"Noah","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":24},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the target and why is it relevant to treatment?","Question",{"text":112,"@type":113},"DLL3 is a cell-surface protein selectively upregulated in high-grade neuroendocrine tumors, with limited presence on normal adult tissue, making it an attractive target for imaging and therapy.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How are the next-generation anti-DLL3 agents designed?",{"text":117,"@type":113},"Selected high-affinity internalizing anti-DLL3 monoclonal antibodies are reformatted as IgG4 to reduce effector function, then produced and conjugated to radionuclides for imaging (89Zr) or therapy (177Lu).",{"name":119,"@type":110,"acceptedAnswer":120},"What do the imaging and therapy results show?",{"text":121,"@type":113},"ImmunoPET identified a leading 89Zr-labeled diagnostic tracer with strong tumor-to-background ratios, while 177Lu-labeled constructs produced significant antitumor effects and improved overall survival in multiple SCLC and NEPC models.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},350992,1790208166,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":24,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":52,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},8796095462418,"https://ap-avatar.wpscdn.com/avatar/80000253c1241d02b47?x-image-process=image/resize,m_fixed,w_180,h_180&k=1778826106357471780","RESEARCH ARTICLE  \nMEDICAL SCIENCES  \n OPEN ACCESS  \nNext-generation anti-DLL3 radiopharmaceuticals targeting high-grade neuroendocrine lung and prostate cancers  \nSalomon Tendlera, b, 1 , Roberto De Gregoriob, Paul Balderesc, Alexa L. Michelb, Tran T. Hoangb, David Bauerb , Kathryn M. Tullyb, Joshua A. Korsenb, Ivo C. Lorenzc, Abdul G. Khanc, Lukas Carterd , Olivia Vergnollec, Irina V. Lebedevac , Elisabeth K. Nyakaturac, Lisa Bodeib , Michael J. Morrisa,e ,  \nJohn T. Poiriera,f,2, Charles M. Rudina,f,g,2 , and Jason S. Lewisb,f,g,2  Affiliations are included on p. 10.  \nEdited by David Carbone, Ohio State University Cancer Center, Columbus, OH; received March 14, 2025; accepted December 23, 2025 by Editorial Board Member Anton Berns  \nDelta-like ligand 3 (DLL3) is a tumor-selective cell surface protein upregulated in high-grade neuroendocrine tumors, including small-cell lung cancer (SCLC) and neuroendocrine prostate cancer (NEPC) . Here, we report on the development of  \nanti-DLL3 radioimmunoconjugates for use as either based on the positron-emitter zirconium-89 (89Zr) orthe beta-emitter lutetium-177 (177Lu) . To begin, we  \na diagnostic imaging tracera therapeutic agent utilizing generated a panel of human  \nmonoclonal antibodies targeting human DLL3 by immunizing transgenic mice engineered with a human immunoglobulin repertoire. The panel was extensively screened to identify high-affinity internalizing monoclonal antibodies (mAbs) recognizing a diversity of DLL3 epitopes. Select mAbs were reformatted as fully human Fab-arm exchange-deficient IgG4 to reduce effector function and then produced by recombinant methods. A pilot immunoPET study was performed in athymic female nude mice bearing human NCI-H82 SCLC tumors to nominate a lead candidate. ImmunoPET identified [89Zr]Zr-DFO-TDI-Y-010 as the top-performing diagnostic tracer, with excellent in vivo biodistribution and tumor-to-background-organ ratios consistently >4 . Therapeutic studies with [177Lu]Lu-CHX-A\"-DTPA-TDI-Y-010 demonstrated strong antitumor effects, significantly improving (P \u003C0.05) overall survival compared with the benchmark clone [177Lu]Lu-CHX-A\"-DTPA-SC16 .56 in two SCLC tumor models (NCI-H82 and Lu149) and achieving comparable overall survival in a NEPC tumor model.  \nTheranostics | DLL3 | SCLC | NEPC | Lutetium-177  \nDelta-like ligand 3 (DLL3) is a cell surface protein that has been identified as a highly selective marker of high-grade neuroendocrine tumors due in part to its absence from the cell surface of normal adult tissues ( 1) . DLL3 is a direct transcriptional target of achaete– scute complex-like 1 (ASCL1), a lineage-defining transcription factor expressed in at least 70% of SCLCs (2). Median survival for patients diagnosed with SCLC is approximately one year from diagnosis, and 5-year survival rates remain in the low single digits. DLL3 is aberrantly overexpressed in other neuroendocrine neoplasms, notably neuroendocrine prostate cancer (NEPC) (2). With the increasing use of potent anti-androgens, up to 15 to 20% of prostate adenocarcinomas demonstrate a histologic shift to NEPC as a mechanism of acquired resistance (3–5). With no durable effective treatments available, NEPC has a prognosis similar to that ofSCLC (6). DLL3-directed therapies, including bispecific T cell engagers (TCEs), have demonstrated clinical efficacy in patients with SCLC, with FDA approval of tarlatamab being the latest breakthrough in SCLC patient care (7) . The mechanism of action of these agents is based on the recruitment and intratumoral activation ofT-cells, leading to tumor cell lysis (7, 8) .  \nRadiotheranostic agents differ from T cell engagers in that they employ an injectable conjugated radionuclide, allowing for molecular imaging or therapy when bound to a tumor-targeting molecule (a full-length monoclonal antibody in this report) . Molecular imaging, e.g., positron emission tomography (PET) with a zirconium-89 (89Zr)-conjugated antibody, can elucidate the ex","cbCairrD3aKU0WN3","https://ap.wps.com/l/cbCairrD3aKU0WN3","pdf",2975733,"English","# Significance\n## Diagnostic tracer development\n## Therapeutic evaluation","[{\"question\":\"What is the target and why is it relevant to treatment?\",\"answer\":\"DLL3 is a cell-surface protein selectively upregulated in high-grade neuroendocrine tumors, with limited presence on normal adult tissue, making it an attractive target for imaging and therapy.\"},{\"question\":\"How are the next-generation anti-DLL3 agents designed?\",\"answer\":\"Selected high-affinity internalizing anti-DLL3 monoclonal antibodies are reformatted as IgG4 to reduce effector function, then produced and conjugated to radionuclides for imaging (89Zr) or therapy (177Lu).\"},{\"question\":\"What do the imaging and therapy results show?\",\"answer\":\"ImmunoPET identified a leading 89Zr-labeled diagnostic tracer with strong tumor-to-background ratios, while 177Lu-labeled constructs produced significant antitumor effects and improved overall survival in multiple SCLC and NEPC models.\"}]","Next-generation anti-DLL3 radiopharmaceuticals targeting high-grade neuroendocrine lung and prostate cancers | PDF",1790092216,25,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/45fcdff172e475da372fcdf4e5aed2c4.webp",983,1316,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/647690de594f38b215ec376d0b91f44d.webp",982,1315,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/16dcc6538b36c98b3fd5b66b57ff3d2b.webp",981,1313,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/658c7667d26f4a09d69965b7019b9eda.webp",980,1312]